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A major challenge in the application of structure-based drug
design methods to proteins belonging to the superfamily of G
protein-coupled receptors (GPCRs) is the paucity of structural
information (1). The 19 chemokine receptors, belonging to the
ClassA family ofGPCRs, are important drug targets not only for
autoimmune diseases like multiple sclerosis but also for the
blockade of human immunodeficiency virus type 1 entry (2).
Using the MembStruk computational method (3), we predicted
the three-dimensional structure of the human CCR1 receptor.
In addition, we predicted the binding site of the small molecule
CCR1 antagonist BX 471, which is currently in Phase II clinical
trials (4). Based on the predicted antagonist binding site we
designed 17 point mutants of CCR1 to validate the predictions.
Subsequent competitive ligand binding and chemotaxis experi-
ments with these mutants gave an excellent correlation to these
predictions. In particular, we find that Tyr-113 and Tyr-114 on
transmembranedomain3 and Ile-259on transmembrane6 con-
tribute significantly to the binding of BX 471. Finally, we used
the predicted and validated structure of CCR1 in a virtual
screening validation of the Maybridge data base, seeded with
selective CCR1 antagonists. The screen identified 63% of CCR1
antagonists in the top 5% of the hits. Our results indicate that
rational drug design for GPCR targets is a feasible approach.
Chemokines belong to a large family of small, chemotactic
cytokines that regulate the trafficking of immune cells (5) by
binding to cell surface receptors belonging to theGPCR3 super-
family (5). CCR1, the first CC chemokine receptor to be iden-
tified, responds to a number of ligands, including MIP-1
(CCL3) and RANTES (regulated on activation normal T cell
expressed and secreted) (CCL5) (6, 7). The strong association
with a wide variety of autoimmune and pro-inflammatory dis-
eases has made the CCR1 protein an attractive therapeutic tar-
get, and Berlex has developed a potent, specific, orally available
antagonist, BX 471, currently in a Phase II clinical trial (8).
The CCR1 antagonist program that yielded the clinical com-
pound BX 471 followed a traditional drug discovery approach
starting with high throughput screening of large compound
libraries (9). Although high throughput screening is a main pil-
lar of drug-finding programs in the pharmaceutical industry, it
has recently been supplemented by in silico methods to maxi-
mize the probability of finding attractive novel leads. Structure-
based in silico approaches have been challenging for GPCRs,
because only one experimental GPCR structure, that of bovine
rhodopsin, with only20% sequence identity toCCR1 (10), has
been reported. Recent developments inGPCR structure predic-
tion methods show great potential for structure-based drug
design and identifying novel hits from virtual screens (11–15).
In this communication we report a significant test of the
computational method MembStruk by predicting the struc-
ture of CCR1. Further, we scanned the entire predicted struc-
ture using theHierDock computational protocol to identify the
binding site of BX 471. Structure and binding site predictions
were subsequently tested experimentally using CCR1 point
mutants. The MembStruk and HierDock methods were vali-
dated for bovine rhodopsin (15) and have been used success-
fully to predict the structure and ligand binding sites for the
2-adrenergic and dopamine D2 receptors (16, 17).
EXPERIMENTAL PROCEDURES
Materials—Unlabeled CCL3 was from Peprotech (London,
UK).125I-Labeled CCL3 was obtained from Amersham Bio-
sciences. All other reagents were purchased from Sigma-Al-
drich and Invitrogen, unless stated otherwise. The monoclonal
anti-HA antibody was purchased from Cambridge Bioscience
(Cambridge, UK). Fluorescein isothiocyanate-conjugated goat
anti-mouse antibody was purchased from DakoCytomation
(Ely, UK).
Generation of HA-tagged CCR1—The amino terminus of
CCR1 was tagged with the HA epitope by PCR using the sense
primer 5-GCGCATAAGCTTGCCACCATGTATCCATAT-
GATGTCCCAGATTATGCCAAAGAATTCGAAACTCCA-
AACACCACAGAGGA-3 and the antisense primer SP6 5-
ATTTAGGTGACACTATAGAATAC-3. The PCR product
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was then inserted back into pcDNA3.1 at the HindIII and XhoI
sites, and its authenticity was verified by fluorescent DNA
sequencing of both strands (MWG-Biotech, London, UK).
Generation of Point Mutants—Point mutants of CCR1 were
generated by PCR using theQuikChange site-directedmutagene-
sis kit, as previously described (18) (Stratagene), according to the
manufacturer’s instructions. The fidelity of each construct was
verified by DNA sequencing on both strands.
Tissue Culture—L1.2 cells weremaintained as described pre-
viously (19) in suspension at 37 °C with 5% CO2 at a density of
no more than 1  106 cells/ml. Cells were transiently trans-
fected by electroporation as described previously (19). In brief,
1 106 cells permicrogram of DNAwere electroporated and
incubated overnight with medium supplemented with 10 mM
sodium butyrate. Cells were harvested and assayed the follow-
ing day. The HEK293 cell line was obtained from the American
Type Culture Collection and was cultured as previously
described (9). Human monocytes were isolated as previously
described (9).
CCR1-expressing Cells—The transfection and selection of
HEK293 cells stably expressing humanCCR1was carried out as
described previously (9).
Flow Cytometry—Approximately 5  105 cells were har-
vested, washed once with fluorescence-activated cell sorting
buffer (0.25% bovine serum albumin and 0.01% NaN3 in phos-
phate-buffered saline) and then incubated with the primary
antibody or the corresponding IgG isotype control for 15min in
a final volume of 100 l. Cells were then washed with fluores-
cence-activated cell sorting buffer and incubated with the fluo-
rescein isothiocyanate-coupled secondary antibody for 15 min
in a final volume of 50l. Subsequently, cells were washed with
fluorescence-activated cell-sorting buffer and resuspended in a
final volume of 400 l before being analyzed by flow cytometry
as described previously (20). The anti-CCR1 antibody was used
at 10 g/ml, the anti-hemagglutinin antibody was used at 5
g/ml, and the fluorescein isothiocyanate-conjugated second-
ary antibody was used at a 1:50 dilution. All incubations were
carried out on ice.
Chemotaxis Assay—Assays of chemotactic responsiveness
were performed using ChemoTxTM plates (Receptor Technol-
ogies Ltd., Oxon, UK) as described previously (19). Briefly, dif-
ferent concentrations of CCL3 in the presence or absence of a
fixed concentration of BX 471 were loaded onto the bottom
wells in a final volume of 31 l of chemotaxis media (HEPES-
modified RPMI 1640 media containing 0.1% bovine serum
albumin). The 5-m pore filter was placed on top of the wells,
and 2 105 cells in a volume of 20l of chemotaxismedia were
loaded onto the filter. Following incubation for 5 h in a humid-
ified chamber at 37 °C with 5% CO2, the numbers of cells
migrating into the well were counted using a hemocytometer.
In a primary screen, the ability of BX471 to inhibit 10 nMCCL3-
induced cell migration in all of the point mutants was assessed
at least three times in triplicate. Mutants of interest were fur-
ther characterized over a greater concentration range of CCL3.
In every experiment, cells transiently expressing the wild-type
CCR1 construct were employed as a positive control.
125I-BX 691 Binding Studies—Binding assays were per-
formed utilizing scintillation proximity assay (SPA) technology
as previously described (9). HEK293 cells expressing human
CCR1 at 20,000 cells or human monocytes at 125,000 cells per
assay point were used as the receptor source. Cells were incu-
bated with 0.1 nM of 125I-BX 691 and 0.05–0.1 mg of WGA-
PVT-SPA beads at room temperature for 1 h. The receptor-
bound 125I-BX 691 excited the scintillant embedded in the
beads and triggered a signal that could be detected by scintilla-
tion counter (Wallac microbeta). Nonspecific binding was
determined in the presence of 100 nM unlabeled BX 691.
125I-CCL3 Binding Studies of CCR1 Mutants—Whole cell
binding assays on transiently transfected L1.2 cells were per-
formed as described previously (21), using 0.05 nM radiolabeled
CCL3 and increasing concentrations of unlabeled competitor.
In all experiments, each data point was assayed in triplicate.
Data are presented as the percentage of counts obtained in the
absence of cold competing ligand. The binding data were curve
fitted with the computer program IGOR (Wavemetrics) to
determine the affinity and number of sites.
MembStruk Structure Prediction Method—The Memb-
Struk3.5 procedure described previously was used to predict
the structure of CCR1 (17). The transmembrane regions and
the hydrophobicmaxima (shown below in bold font and under-
lined) were predicted using the TM2ndSmethod with multiple
sequence alignment that includes all chemokine receptor
sequences. The predicted TM regions were: TM1, QLLPPLYSL-
VFVIGLVGNILVVLVLVQYK;TM2, SIYLLNLAISDLLFLFTLP-
FWIDYKLK; TM3, AMCKILSGFYYTGLYSEIFFIILLTIDRYLA-
IVH; TM4, TFGVITSIIIWALAILASMPGLYF; TM5, ALKLNLF-
GLVLPLLVMIICYTGII;TM6,RLIFVIMIIFFLFWTPYNLTILIS-
VFQDF; and TM7, TEVIAYTHCCVNPVIYAFVGER.
Subsequent optimization of the relative translation, rota-
tional orientation, and the kinks and bends of the transmem-
brane helices were performed as described previously (15).
Alternate well packed low energy rotational orientations were
also generated as described previously (22). The rotational
angle scanning for helix7 was performed by protonating His-
293 due to the proximity of Glu-120 on helix3. Extra- and intra-
cellular loops were added using Modeler6v2, and the second
extracellular loop was optimized as described previously (22).
The resulting structure has the following interhelical hydrogen
bonds. Asp-80(TM2) makes a 2.9-Å hydrogen bond with Asn-
297(TM7). Asn-52(TM1) makes a 2.1-Å hydrogen bond with
Asp-80(TM2). These hydrogen bonds are between the most
conserved residues in the class A rhodopsin-like GPCRs. There
is also a 2.9-Åhydrogen bond betweenAsn-297(TM7) andGlu-
120(TM3). Glu-120(TM3) also makes a hydrogen bond with
His-293 onhelix 7. There is aweak or perhaps awater-mediated
hydrogen bond between Asn-75(TM2) and Trp-158(TM4) and
between Ser-79(TM2) and Ser-119(TM3).
Prediction of the Binding Site for BX 471—The void space in
the entire receptor structure was divided into 14 regions of 7
7  7 Å3 volume, and HierDock calculations were performed
(3) to determine the binding site of BX 471. Using quantum
mechanical calculations, the pKa of BX 471was calculated to be
neutral at normal pH. BX 471 was subsequently docked into
this binding region using the HierDock procedure with pro-
tein-movable optimization (3). Subsequent to docking the
binding energies were calculated as, BE  PE (ligand in fixed
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protein)  PE (ligand in solvation), where BE is the binding
energy, PE (ligand in fixed protein) is the potential energy of the
ligand calculatedwith the protein atoms fixed, and PE (ligand in
solvation) is the potential energy of the ligand calculated with
the analytical volume-generalized Born continuum solvation
method. The docked structurewith the best binding energywas
selected for analysis and molecular dynamics simulations.
Virtual Screen—Using GOLD 2.1 (23), we docked all com-
pounds of a filtered version of the Maybridge data base spiked
with 35 known CCR1 antagonists from our in-house optimiza-
tion project and kept the top 50 conformations for each com-
pound. The docked configurations were scored by the sum of
the van der Waals and Coulomb protein-ligand interaction
energies, using Dock 4.0.1 (24). The top scoring 50% of com-
pounds were further optimized in a 50-conjugate gradient step
minimization, using the Universal 1.0.2 force field as imple-
mented in Cerius2. The five lowest energy structures are fur-
ther minimized for 250 steps. Note that all minimizations are
performed in fixed protein. Finally, we calculate the desolvation
penalty for the best configuration of each compound using the
generalized Born solvation method as implemented in-house
(25). Our final score is the sum of Coulomb, van derWaals, and
desolvation energies.
RESULTS ANDDISCUSSION
The predicted structure for CCR1 is shown in Fig. 1, along
with the binding site of BX471 that is located betweenTMs 3, 4,
5, 6, and 7. The strongest protein-ligand interactions in the
predicted structure are predominantly of hydrophobic charac-
ter. They arise from Tyr-113(TM3) and Ile-259(TM6), which
anchor the piperazine ring, and Tyr-114(TM3), which provides
pi-stacking interactions to the adjacent phenyl ring with the
FIGURE 1. The structure of human CCR1 predicted usingMembStruk showing the BX 471 antagonist binding site predicted using HierDock. A, a side
viewwith the extracellular region at the top. B, a top view of the predicted structure of BX 471 in the CCR1 binding pocket. The residues shown in red (Tyr-113,
Tyr-114, and Ile-259) are responsible for anchoring the ligand in this cavity.C, details of the predicted binding site (top view), showing all residueswithin 5Å for
the BX 471 ligand. Here, red indicates the residues contributing most to the binding.
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urea group (red residues in Fig. 1, B and C). Neither tyrosine
forms strong hydrogen bonds to BX 471. The fluorine on BX
471 interacts favorably with one of themethyl groups of Leu-87
and with the phenyl ring of Phe-83. The urea group of BX 471
does not make tight polar interactions with the protein,
although it can hydrogen-bond to the carbonyl group of the
Gly-168 backbone or the OH-group of Tyr-114. The structure
activity relationship from our medicinal chemistry optimiza-
tion program for this particular substituent indicates that it is
not an important site for protein-ligand interactions, because
many different substituents of different sizes and polarities are
tolerated in this position. Molecular dynamics simulations of
the CCR1/BX 471 complex in explicit lipid bilayer and water
indicate that this group is highly flexible and forms hydrogen
bonds with water molecules that enter the binding region.
Molecular dynamics simulation shows that the CCR1 structure
with BX 471 bound is stable over the entire 10 ns of simulation
time. Because the prediction of the
loop structures is associated with a
large degree of uncertainty, we
ignored the contribution of residues
in the loop to binding.
To verify the predicted binding
site of BX 471, we constructed a
series of 17 receptor mutants (Fig.
2). These mutants included key res-
idues predicted to be in the bind-
ing pocket for BX 471 (Tyr-113,
Tyr-114, and Ile-259) together with
residues Tyr-41, Glu-287, and Tyr-
291, identified as playing a role in
antagonist binding in previous stud-
ies with charged CCR1 antagonists
(18, 26). Cells separately transfected
with either wild-type CCR1 or with
point mutants of CCR1 predicted to
be outside the antagonist binding
site were included as controls (Fig.
2). The point mutants were all tran-
siently expressed at high levels on
the surface of L1.2 cells as detected
by flow cytometry after incubation
with an antibody to an epitope tag at
the receptor amino terminus (Fig.
2A). The CCR1 point mutants were
then screened for antagonismby BX
471 of chemotactic responses to 10
nMCCL3 (Fig. 2B). Several mutants,
including Y41A, Y113A, Y114A,
I259A, and Y291A were very resist-
ant to inhibition by BX 471, and full
dose-response curves for these and
other selected mutants were carried
out. The functional assays revealed
that BX 471 has an IC50 greater than
10 M for inhibition of chemotaxis
in the Y113A, Y114A, and I259A
mutants (Fig. 3A and Table 1), as
expected from the model. Other mutants, including Y41A and
Y291A, were also resistant to inhibition of chemotaxis by BX
471 (Fig. 3A and Table 1), consistent with the predictions.
The CCR1 point mutants were next tested for the ability of
BX 471 to displace the specific binding of 125I-CCL3 to the
wild-type and mutant receptors (Fig. 3B and Table 1). Compe-
tition binding assays revealed that the mutations Y113A and
Y114A on TM3 and I259A on TM6 resulted in a significant
reduction in binding of BX 471, in line with the data from the
chemotaxis assays. Specifically, whereas the antagonist binds to
the wild-type receptor with an IC50 of 10 nM, the IC50 for the
Y113A and I259A mutants is 10 M, and for Y114A it is 5
M. The large effects of these three mutations on BX 471 bind-
ing had been predicted in the computational mutation studies
that showed a change in binding energy of 6.28, 5.79, and 9.24
kcal/mol, respectively, for these three mutants (Table 1). The
large decrease in binding energy predicted for Y113A, Y114A,
FIGURE 2. Receptor expression and screening of the ability of BX 471 to inhibit CCL3-inducedmigration
of CCR1 point mutants. A, cell surface expression of CCR1 point mutants. Each of the HA-tagged CCR1 point
mutant constructswas transiently transfected independently into L1.2 cells aspreviouslydescribed (18). Twen-
ty-four hours after transfection, cells were incubated with anti-HA antibody, and cell surface expression was
analyzed by flow cytometry. Surface expression is shown as a percentage of the expression observed for cells
simultaneously transfectedwith thewild-type CCR1 construct. Data are representative of a typical experiment
of at least two independent experiments. B, the ability of BX 471 to inhibit CCL3-induced chemotactic
responses of L1.2 cells transiently expressing the CCR1 point mutants. The panel of CCR1 mutants was tested
for the ability to migrate in response to 10 nM CCL3 in the presence or absence of 100 nM of BX 471. The
percentage inhibitionwas calculatedusing this equation:% inhibition100 ((thenumber of cellsmigrating
in the presence of the agonist the number of cellsmigrating in the absence of the antagonist) 100).Where
no chemotaxis was observed in the presence of the antagonist, inhibition was described as 100%. Data are
shown as % inhibition of chemotaxis by BX 471 S.E. from three independent experiments.
FIGURE 3. BX 471 inhibition of CCL3-mediated chemotaxis and radiolabeled CCL3 binding to L1.2 cells
transiently expressing selected CCR1 pointmutants. A, dose-response curves of BX 471 inhibition of CCL3-
induced chemotactic responses of L1.2 cells transiently expressing selected CCR1 point mutants. The inhibi-
tion of the responses of each construct to a 10 nM concentration of CCL3 is illustrated. Data are representative
of a typical experiment of at least two independent experiments. B, dose-response curves of BX 471 inhibition
of radiolabeled CCL3 binding to L1.2 cells transiently expressing selected CCR1 point mutants. Data are repre-
sentative of a typical experiment of at least two independent experiments.
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and I259A arises predominantly from the loss of favorable van
der Waals interactions of the phenyl containing residues with
the piperazine ring in BX 471. Indeed, the calculations followed
by experiments show that replacement of Tyr-113 by pheny-
lalanine (Y113F) has aminimal effect on the ability of BX 471 to
inhibit binding or chemotaxis, compared with a total inability
of the antagonist to inhibit either process in the Y113Amutant
(see Fig. 3 and Table 1).
Interestingly the residues Tyr-41, Glu-287, and Tyr-291,
which were identified to bind to the protonated antagonist
UCB35625 (18), andGlu-287, which has also been implicated in
the binding of another protonated antagonist, BX 510 (26), are
not part of the binding pocket for BX 471 even though we do
observe changes in experimental binding and activation studies
with these mutants. Y41A(TM1) makes a strong (2.85 Å) inter-
helical hydrogen bond to Glu-287(TM7), which is well pre-
served during the molecular dynamics simulations in explicit
water and lipid with antagonist bound. Tyr-291(TM7) is one
turn below Glu-287(TM7) and has a loose aromatic stacking
interaction with Tyr-41(TM1). We speculate that this network
of hydrogen bonding between Tyr-41 and Glu-287 combined
with aromatic stacking between Tyr-41 and Tyr-291 is impor-
tant for structural stability, and therefore mutation of any of
these residues affects both binding and activation of CCR1. In
contrast, these residues play only a minor role in binding the
neutral antagonist BX471,whereTyr-113, Tyr-114, and Ile-259
play the most important role. Thus, the binding site of the neu-
tral antagonist BX 471 is shifted toward helices 3, 6, and 7 com-
pared with the binding site of protonated antagonists that lies
closer to helices 1 and 2.
A major assumption in receptor mutagenesis studies is that
any loss of function observed is due to the mutation alone and
does not involve structural changes in the molecule. Such an
assumption is generally valid for surface residues but is not
necessarily true for buried/structural large hydrophobic or aro-
matic residues. Because the residues we have identified as
important for binding in this study, Tyr-113, Tyr-114, and Ile-
259, are buried hydrophobic or aromatic residues, it was impor-
tant to determine that the mutations did not perturb the struc-
ture and function of the receptor. To test the structural
integrity of the three CCR1mutants Y113A, Y114A, and I259A
we carried out both displacement binding and chemotaxis
studies with the CCR1 ligand CCL3. The binding studies
revealed (Fig. 4B) that all three mutants had very similar affin-
ities for binding of CCL3 (WTKi 31.8 16.1 nM; Y113AKi
22.3 3.1 nM; Y114AKi 15.3 3.3 nM; I259AKi 14.7 4.9
nM). In addition all threemutants responded chemotactically in
a similar dose-responsive manner as wild-type CCR1 to
increasing concentrations of CCL3 (Fig. 4A). These data
strongly suggest that the structural integrity of these mutants
with respect to chemokine binding and activation is not altered.
We cannot rule out, however, that
structural changes have occurred in
these mutants that would not be
manifested by changes in chemo-
kine function. We do think that this
is unlikely, however, for several rea-
sons. First, we see robust expression
of the CCR1 mutants compared with
wild-type CCR1, and misfolded pro-
teins would tend to exhibit lower
expression. Second, in the apo-pro-
tein structure of CCR1 (after 10 ns of
molecular dynamics simulation in
explicit lipid bilayer and water),
Tyr-113(TM3) has favorable van
der Waals interactions with Ile-
259(TM6) and hydrogen bond inter-
action with Thr-286(TM7). Tyr-114
FIGURE 4. CCL3 inhibition of CCL3-mediated chemotaxis and radiolabeled CCL3 binding to L1.2 cells
transiently expressing selected CCR1 point mutants. A, dose-response curves of CCL3-induced chemotac-
tic responses of L1.2 cells transiently expressing selected CCR1 point mutants. Data are representative of a
typical experiment of at least two independent experiments. B, dose-response curves of CCL3 inhibition of
radiolabeled CCL3 binding to L1.2 cells transiently expressing selected CCR1 point mutants. Data are repre-
sentative of a typical experiment of at least two independent experiments.
TABLE 1
Summary of experiments on the effect of CCR1mutations on BX 471
inhibition of CCL3-induced receptor binding and chemotaxis
Changes in binding energies are calculated as the difference in binding energy of BX
471 to the wild-type receptor compared with binding to the mutant receptor. Bind-
ing energy potential energy of ligand (in protein) potential energy of ligand (in
solvent). Binding energies are reported in kcal/mol, and a more positive number
indicates a decrease in affinity of the antagonist for the receptor.
Mutant IC50 BX 471inhibit binding Ratio
Calculated
change in BE
nM
Wild type 10 5 1 0.0
Y113A 10,000 1,000 6.28
I259A 10,000 1,000 5.79
Y114A 5,017 1970 502 9.24
I91A 849 287 85 0.55
Y291A 542 308 54 0.04
Y113F 464 164 46 1.49
T86A 348 180 35 0.52
E287Q 344 122 34 0.06
Y41A 264 179 26 0.02
L260A 58 6 6 0.03
Mutant IC50 BX 471inhibit migration Ratio
nM
Wild type 3.4 0.54 1
Y113A 10,000 2,941
Y114A 10,000 2,941
I259A 10,000 2,941
Y41A 541 54 159
Y291A 491 70 144
E287Q 284 102 83
I91A 233 73 68
T86A 77.9 34 23
Y113F 16 6 5
L260A 2.3 0.88 1
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on TM3 has weak van derWaals interactions with Val-263(TM6)
and Tyr-113(TM3). Ile-259 makes van der Waals contact with
Leu-208(TM4) and Val-263(TM6). In the Y113Amutant, the
loss of hydrogen bond interaction
with Thr-286 is partially compen-
sated for by the favorable interac-
tion of the methyl group of Ala-
113 with the methyl group of Thr-
286(TM7). We speculate that this
hydrogen bond is not a critical
structural factor, because mutat-
ing Tyr-113 3 Ala or Tyr-113 3
Phe did not affect the cell surface
expression levels of these mutants.
Y114A and I259A mutants simi-
larly have weaker van der Waals
interactions that may not impair
the folding of the receptor. Based
on these observations along with
the robust level of cell surface expression seen for these
mutant receptors, we speculate that mutation of these resi-
dues to Ala does not affect the structural integrity of the
receptor. This validates our contention that they play a key
role in ligand binding of the antagonist BX 471.
The chemokine receptor antagonist BX 471 is highly specific
for CCR1. Previous work has shown that it has no cross-reac-
tivity at concentrations10 M with 30 other GPCRs, includ-
ing several chemokine receptors (9). The only exception is the
low affinity binding to CCR3with aKi of 1.4M. CCR3 has 63%
sequence identity to CCR1, and the residues Tyr-113, Ile-259,
Ile-91, and Tyr-291 are conserved between the two receptors.
Based on our model we speculate that the basis for the low
affinity binding of BX 471 to CCR3 is partly due to the conser-
vation of residues Tyr-113 and Ile-259 in CCR3 that have been
shown to be important in the binding of BX 471 to CCR1.
To further characterize the CCR1 antagonist binding site we
utilized a 125I-labeled CCR1 antagonist generated by replacing
the chloro-group on the benzyl ring of BX 471 with an iodo-
group. The resulting compound BX 691 is a functional antago-
nist for CCR1 with similar potency (Ki 1.7 nM). Because BX 471
and BX 691 behave similarly as CCR1 antagonists, 125I-BX 691
was used to characterize the direct interaction of small mole-
cule CCR1 antagonists with CCR1. 125I-BX 691 binds to CCR1
on human monocytes as well as on HEK293 cells that express
the receptor (Fig. 5). The binding is dose-responsively inhibited
by unlabeled BX 471 and BX 691, with affinities similar to those
for displacing 125I-CCL3 binding (Fig. 5). However, the CCR1
agonists CCL3, CCL5, and CCL7 failed to displace 125I-BX 691
binding to CCR1, suggesting that they do not bind to the same
site on the receptor as the antagonists. These data clearly sug-
gest that BX 471 and BX 691 are allosteric antagonists of CCR1
and bind to sites on the receptor that are non-overlapping and
distinct from the agonist binding site. Indeed, structure-func-
tion studies have revealed that chemokines such as CCL3 bind
to CCR1 via residues in the N terminus and in the extracellular
loops (27, 28). In contrast, we have shown here that BX 471, like
other chemokine receptor antagonists (29, 30), binds to CCR1
in the transmembrane domain, similar to the transmembrane
binding domain of 11-cis-retinal in rhodopsin. Through its
interaction with residues in the transmembrane domain, BX
471 induces a conformational change in the receptor that leads
FIGURE 5. Inhibition of 125I-BX 691 binding to human CCR1 by unlabeled antagonists and agonists on
HEK293 cells stably expressing CCR1 (A) and humanmonocytes (B). Cells were incubated for 60 min at room
temperature with 125I-BX 691 in the presence of increasing concentrations of compounds or chemokines. The
bound 125I-BX 691 was determined using SPA technology. Nonspecific binding was defined as the binding in the
presenceof 1MofunlabeledBX691.Data are shownas total bindingS.E. fromthree independent experiments.
TABLE 2
Correlation between the calculated change in binding energies (BE)
and experimental binding affinities for human CCR1 docked with
CCR1 antagonists
The structures of a few CCR1 antagonists are shown. The calculated change in
binding energies for the second compound in each table is relative to the first
compound in each table, which has a normalized reference energy of 0.0 kcal/mol. A
positive change in BE indicates lower affinity of the antagonist for the receptor.
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to displacement of bound chemokine from its extracellular
binding site. In contrast, when radiolabeled BX 471 is bound,
CCR1 agonists are unable to competitively displace the
antagonist.
To further validate the predicted structure and binding site,
we docked several antagonists, belonging to the same pipera-
zine template as BX 471, to CCR1 (Table 2). The model clearly
distinguishes strong from weak binders according to their cal-
culated binding energies. Thus, we believe that structure-based
design using GPCR models can be used in future projects
during the medicinal chemistry optimization phase of lead
compounds.
Lastly, we performed a retrospective virtual ligand screen
using the predicted structure and binding site of BX 471 to
explore if the model could be used in the lead identification
process. To this end, we docked a filtered version of the May-
bridge data base (51,000 compounds) enriched with 35
known CCR1 antagonists ranging in affinity between 1 and
1000 nM, which represent four different chemical templates
(some representative structures are shown in Table 2) into the
predicted structure without loops. We used a hierarchical vir-
tual ligand screen procedure as described under “Experimental
Procedures.” The results of the virtual screen showed that 43%
of all CCR1 actives were recovered in the top 2% of screened
molecules and 63% of the known CCR1 antagonists scored
within the top 5% of the screened molecules (Fig. 6). This cor-
responds to a hit enrichment of 21 times over randomat 2% and
13 times over random at 5% of the data base screened, where
enrichment factors have been calculated as in a previous study
(11). These data demonstrate that predicted GPCR structures
are useful in a structure-based in silico drug discovery process
andunderscore the ability of theCCR1model to retrieve seeded
CCR1 antagonists frommultiple templates with high efficiency
from a chemical data base. This is important, because it vali-
dates the model in addition to the validation provided by the
experimentally determined binding and activation data de-
scribed earlier. The next logical step in this process will be to
utilize the model in a prospective virtual screen to identify new
CCR1 actives from commercially available chemical databases.
Hopefully this will aid and abet the drug discovery process
by finding new lead compounds to supplement traditional
approaches that utilize high throughput screening of com-
pound libraries.
In conclusion, we predicted a structure of the human chemo-
kine receptor CCR1 using the MembStruk computational
method. Additionally, we predicted the binding site of the neu-
tral antagonist BX 471 in CCR1 using the HierDock computa-
tional method. The structure suggested that the residues Tyr-
113, Tyr-114, and Ile-259 are themost important for binding of
the antagonist BX 471 to CCR1. We then validated the pre-
dicted antagonist binding site in CCR1 using mutational anal-
ysis. Further, we used the protein structure to successfully iden-
tify CCR1 antagonists in a retrospective virtual ligand screen of
a large data base, demonstrating the utility of structure-based in
silicomethods in the hit-finding process of GPCR antagonists.
Our results suggest that structure-based in silico rational drug
design for GPCR targets is feasible.
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